Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery

被引:8
作者
Melnik, G
Schwesinger, WH
Dogolo, LC
Teng, RL
Vincent, J
机构
[1] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA
[2] Pfizer Inc, Pfizer Cent Res, Groton, CT 06340 USA
关键词
D O I
10.1016/S0002-9610(98)00214-1
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Trovafloxacin is a new fourth-generation fluoroquinolone whose pharmacokinetics and in vitro activity suggest that it is well suited for antibiotic prophylaxis in elective colorectal surgery. Alatrofloxaccin is a prodrug that is rapidly hydrolyzed to trovafloxacin in the body. METHODS: Twelve patients received a single dose of alatrofloxacin equivalent to 200 mg trovafloxacin by intravenous infusion over 1 hour. Surgery was started at various time points relative to infusion time to allow determination of trovafloxacin concentrations in serum, colonic tissue, and peritoneal fluid as a function of time. RESULTS: The concentration in the earliest colonic tissue sample (1.4 hours after dosing) was 1.4 mu g/g. The maximum colonic tissue concentration was 2.8 mu g/g in a sample taken 2 hours after dosing. Colonic tissue/serum concentration ratios in samples taken 2-10 hours after the end of infusion ranged from 0.8 to 1.47. Concentrations of trovafloxacin in peritoneal fluid ranged from below the level of quantitation to 2.1 mu g/mL at the time of colonic tissue sampling and from below the level of quantitation to 2.5 mu g/mL at the time of wound closure. Alatrofloxacin was well tolerated. CONCLUSIONS: After a single intravenous dose of alatrofloxacin equivalent to 200 mg trovafloxacin, trovafloxacin is distributed rapidly into colonic tissue and peritoneal fluids. Tissue concentrations approximate serum concentrations and decline in parallel for up to 10 hours after dosing. (C) 1998 by Excerpta Medica, Inc.
引用
收藏
页码:14S / 17S
页数:4
相关论文
共 17 条
[11]   ACTIVITY OF CP 99,219 COMPARED WITH THOSE OF CIPROFLOXACIN, GREPAFLOXACIN, METRONIDAZOLE, CEFOXITIN, PIPERACILLIN, AND PIPERACILLIN-TAZOBACTAM AGAINST 489 ANAEROBES [J].
SPANGLER, SK ;
JACOBS, MR ;
APPELBAUM, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (10) :2471-2476
[12]   PHARMACOKINETICS AND SAFETY OF TROVAFLOXACIN (CP-99,219), A NEW QUINOLONE ANTIBIOTIC, FOLLOWING ADMINISTRATION OF SINGLE ORAL DOSES TO HEALTHY MALE-VOLUNTEERS [J].
TENG, RL ;
HARRIS, SC ;
NIX, DE ;
SCHENTAG, JJ ;
FOULDS, G ;
LISTON, TE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (02) :385-394
[13]   Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers [J].
Teng, RL ;
Liston, TE ;
Harris, SC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (05) :955-963
[14]   In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli [J].
Thadepalli, H ;
Reddy, U ;
Chuah, SK ;
Thadepalli, F ;
Malilay, C ;
Polzer, RJ ;
Hanna, N ;
Esfandiari, A ;
Brown, P ;
Gollapudi, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :583-586
[15]   Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin [J].
Vincent, J ;
Venitz, J ;
Teng, R ;
Baris, BA ;
Willavize, SA ;
Polzer, RJ ;
Friedman, HL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :75-80
[16]   In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria [J].
Wexler, HM ;
Molitoris, E ;
Molitoris, D ;
Finegold, SM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2232-2235
[17]  
1995, MED LETT DRUGS THER, V37, P79